Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)
$4.5300
-0.4600 ( -8.49% ) 612.3K
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Market Data
Open
$4.5300
Previous close
$4.9900
Volume
612.3K
Market cap
$302.65M
Day range
$4.5300 - $5.0070
52 week range
$1.3000 - $10.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 19 | Dec 18, 2024 |
10-q | Quarterly Reports | 77 | Nov 12, 2024 |
8-k | 8K-related | 15 | Nov 12, 2024 |
8-k | 8K-related | 14 | Oct 23, 2024 |
10-q | Quarterly Reports | 76 | Aug 06, 2024 |
8-k | 8K-related | 16 | Aug 06, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |